The role of CIP2A in oral squamous cell carcinoma

Cancer Biology and Therapy

Volumn 10, Issue 7, 2010, Pages 700-702

  Basile, John R ^a   Czerninski, Rakefet ^b  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

CIP2A; MYC; Oral squamous cell carcinoma; PP2A; Ras

Indexed keywords

AUTOANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN CANCEROUS INHIBITOR OF PP2A; PROTEIN PHOSPHATASE 2 A; UNCLASSIFIED DRUG;

CARCINOGENESIS; DYSPLASIA; HUMAN; MALIGNANT TRANSFORMATION; MOUTH CARCINOMA; NOTE; ORAL SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

AUTOANTIGENS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; MOUTH DISEASES; MOUTH NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77957578394     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.7.13151     Document Type: Note

References (21)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA Cancer J Clin 2010; 60.
2. Mao L, Hong WK. Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004; 5:311-6.
3. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008; 14:152-60.
4. Junttila MR, Li SP, Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2008; 22:954-65.
5. Oliver CJ, Shenolikar S. Physiologic importance of protein phosphatase inhibitors. Front Biosci 1998; 3:961-72.
6. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, et al. CIP2A expression and localization In oral carcinoma and dysplasia. Cancer Biol Ther 2010; 10:694-99.
7. Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56 alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 2008; 27:147-58.
8. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004; 5:127-36.
9. Fujiki H, Suganuma M. Carcinogenic aspects of protein phosphatase 1 and 2A inhibitors. Prog Mol Subcell Biol 2009; 46:221-54.
10. Tanimukai H, Kudo T, Tanaka T, Grundke-Iqbal I, Iqbal K, Takeda M. Novel therapeutic strategies for neurodegenerative disease. Psychogeriatrics 2009; 9:103-9.
11. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003; 4:69.
12. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8:976-90.
13. Cole MD, Henriksson M. 25 years of the c-Myc oncogene. Semin Cancer Biol 2006; 16:241.
14. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008; 7:592-6. (Pubitemid 351498996)
15. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14:2501-14.
16. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003; 278:51606-12.
17. Larsson LG, Henriksson MA. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 2010; 316:1429-37.
18. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 2004; 6:308-18.
19. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' autoantigen of p62 overexpressed in cancer. Oncogene 2002; 21:5006-15.
20. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130:51-62.
21. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence or differentiation of tumor cells. Clin Cancer Res 2008; 14:3722-8.